Hospital Direct (GPO-Contracted) Market Analysis
Cross-industry research covering Hospital Direct (GPO-Contracted) across 2 market reportsspanning Pharmaceuticals & Medical Devices — Ophthalmic Surgery, Pharmaceuticals.
Reports Covering Hospital Direct (GPO-Contracted)
Oculoplastic Surgery Market to Reach USD 8.4 Billion by 2033 at 7.2% CAGR
The dominant channel for surgical implants and IV biologic infusions, where GPO contracts (Vizient, Premier, Intalere) set volume-based pricing tiers; originator device manufacturers accept 15–25% discounts from list in exchange for formulary inclusion, compressing net prices but ensuring volume predictability.
29%
Market Share
5.6%
Segment CAGR
Hospital Acquired Infection Control Market to Reach USD 41.6B by 2033 at 6.4% CAGR
GPO-negotiated hospital direct purchasing dominates IV antibiotic and antifungal distribution in North America and Western Europe. Cardinal Health's USD 222.58B distribution revenue (edgar:CAH-10K-2025) reflects the scale of this channel. GPO formulary inclusion decisions effectively gate market access for novel anti-infectives and can delay real-world adoption by 12–18 months post-FDA approval.
45%
Market Share
5.9%
Segment CAGR